Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1229)	3/3/1998 10:15:00 PM
From: The Gambler	Respond to of 2173

===OFF TOPIC=== Hi Rudy, I agree with you regarding re-priotization of funding. I think this not only happens with merged cos., but also an ongoing business decision. As you know, it's part of the "game", that if there is a better investment opportunities elsewhere, monies will be allocated accordingly and past expenses should not impair business decision for future investments. Here is how I see the similarity. JNJ goes for the "sure" bet, just like HMRI, and soon enough the funding of the research become questionable. The break-up of ALTN/HMRI was under the pretext of R&D fundings priotization due to their merged co. Whether efficacy of studies has or has not been established, was not mentioned. If I remember correctly, I think the break-up happened after the fact of toxicity was announced. AMLN, otoh, has to announce the less than satisfactorily result of it's findings, which if I'm not mistaken has since half-heartedly admitted the less than perfect design in it's studies.(There were interesting and intelligent discussions regarding the result of studies by Henry Niman, D. Right, MBogdanov and some other..please excused my less than perfect spelling here) From the business decision standpoint, it's a prudent decision. No one knows whether the research will be proven up to expectation and there's another opportunity to jump ship. The question for AMLN now, is, where do we go from here? In this regard I agree with Henry that the stock will linger at current price and disagree in that it will go much lower based on the not-yet-capitalized result of research, which easily worth more than $100M. We'll see what will happen next!